Separation of anxiety and depressive disorders

BMJ 2003; 327 doi: 10.1136/bmj.327.7419.870 (Published 9 October 2003)
Cite this as: BMJ 2003;327:870.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Maybe pharmaceutical failure has created culture of niche diagnosis

  1. Michael Joffe, reader in epidemiology (m.joffe@imperial.ac.uk)
  1. Department of Epidemiology, Imperial College, St Mary's Campus, London W2 1PG

    EDITOR—Shorter and Tyrer provide an important case study in the way that medicine and science can become subverted by commercial pressures.1 On one hand, new patents for drugs for mood and anxiety disorders have dwindled to almost nothing from a high point in the 1960s and 1970s. On the other, niche diagnoses have proliferated, apparently as a result of collusion between …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL